By Application
Hot products 
-
Rabbit Anti-BAD (Phospho-Ser136) Recombinant Antibody (CAP219) (CBMAB-AP536LY)
-
Mouse Anti-ATM Recombinant Antibody (2C1) (CBMAB-A3970-YC)
-
Mouse Anti-FTH1 Recombinant Antibody (CBXF-1896) (CBMAB-F3426-CQ)
-
Mouse Anti-BrdU Recombinant Antibody (IIB5) (CBMAB-1038CQ)
-
Mouse Anti-BRD3 Recombinant Antibody (CBYY-0801) (CBMAB-0804-YY)
-
Mouse Anti-BMI1 Recombinant Antibody (CBYC-P026) (CBMAB-P0108-YC)
-
Rat Anti-4-1BB Recombinant Antibody (V2-1558) (CBMAB-0953-LY)
-
Rat Anti-C5AR1 Recombinant Antibody (8D6) (CBMAB-C9139-LY)
-
Mouse Anti-ACVR1C Recombinant Antibody (V2-179685) (CBMAB-A1041-YC)
-
Mouse Anti-DMD Recombinant Antibody (D1190) (CBMAB-D1190-YC)
-
Mouse Anti-CD19 Recombinant Antibody (CBXC-1224) (CBMAB-C1491-CQ)
-
Mouse Anti-FeLV g27 Recombinant Antibody (1) (CBMAB-V208-1714-FY)
-
Rabbit Anti-AKT2 (Phosphorylated S474) Recombinant Antibody (V2-556130) (PTM-CBMAB-0605LY)
-
Mouse Anti-BCL2L1 Recombinant Antibody (H5) (CBMAB-1025CQ)
-
Mouse Anti-CRTAM Recombinant Antibody (CBFYC-2235) (CBMAB-C2305-FY)
-
Mouse Anti-ACO2 Recombinant Antibody (V2-179329) (CBMAB-A0627-YC)
-
Mouse Anti-GluRIIA Monoclonal Antibody (8B4D2) (CBMAB-0305-CN)
-
Mouse Anti-CIITA Recombinant Antibody (CBLC160-LY) (CBMAB-C10987-LY)
-
Rat Anti-FABP3 Recombinant Antibody (CBXF-2299) (CBMAB-F1612-CQ)
-
Mouse Anti-ADRB2 Recombinant Antibody (V2-180026) (CBMAB-A1420-YC)
Skin Cancer (SCC)
Fig.1 Squamous cell skin cancer
Squamous-cell skin cancer, also named as cutaneous squamous-cell carcinoma (cSCC), is one of the typical types of skin cancer along with melanoma and basal cell cancer. Normally, it presents as a hard lump with a scaly top but can also deteriorate into an ulcer. Onset is often several months. Squamous-cell skin cancer is more likely to spread to distant areas comparing with basal cell cancer. The greatest risk factor is the high total exposure to ultraviolet radiation from the sun. Squamous cell cancers happening in the ears and lip have high possibilities of local recurrence and distant metastasis (about 20–50%). SCCs represent around 20% of the non-melanoma skin cancers, but on account of their more obvious nature and growth rates, they stands for 90% of all head and neck cancers that are primarily presented. CD10, as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma, has been studied.
Loading...
Compare
